SCHEMBL6049200

SCHEMBL6049200

CS(=O)(=O)Nc1ccc(Oc2ccc(OC(F)(F)F)cc2)c(C2CCCN2C(=O)O)c1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KIF11 P52732 1/20 0.45
▸ EPHX2 P34913 9/20 0.44
▸ NR1H4 Q96RI1 1/20 0.42
▸ SLC6A2 P23975 1/20 0.41
▸ SLC6A4 P31645 1/20 0.41
▸ SLC6A3 Q01959 1/20 0.41
▸ FPR2 P25090 1/20 0.40
▸ KIT P10721 1/20 0.39
▸ IDH1 O75874 1/20 0.39
▸ LIPE Q05469 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ BRD4 O60885 1/20 0.39
▸ SCD5 Q86SK9 1/20 0.39
▸ MAPT P10636 2/20 0.38
▸ LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7170392 0.91 EPHX2 (0.42) EPHX2LIPEKMT2ABRD4SCD5
SCHEMBL6049181 0.91 SLC6A4 (0.52) KIF11EPHX2NR1H4SLC6A2SLC6A4
SCHEMBL6049210 0.83 SCD5 (0.38) EPHX2SLC6A2SLC6A4SLC6A3BRD4
SCHEMBL6049231 0.82 EPHX2 (0.41) EPHX2LIPEKMT2ABRD4SCD5
SCHEMBL6049191 0.78 GCK (0.43) EPHX2KMT2ASCD5MAPT
SCHEMBL6049192 0.78 GCK (0.43) EPHX2KMT2ASCD5MAPT
SCHEMBL6049203 0.77 KIF11 (0.48) KIF11EPHX2NR1H4SLC6A2SLC6A4
Hydrochloric Acid SCHEMBL7522746 0.76 KIF11 (0.47) KIF11EPHX2NR1H4SLC6A2SLC6A4
SCHEMBL6049224 0.72 KIF11 (0.60) KIF11EPHX2NR1H4SLC6A2SLC6A4
SCHEMBL6049238 0.70 PPARG (0.52) KIF11EPHX2NR1H4SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1184372-B1 Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) PFIZER LTD (GB) 2006-04-26 — — EP disclosed
US-6630504-B2 Activity as selective serotonin re- uptake inhibitors (SSRIs); for therapy and prophylaxis of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, sexual dysfunction PFIZER INC. 2003-10-07 — — US disclosed
US-20020183303-A1 Phenoxyphenylheterocyclyl derivatives as SSRIs PFIZER INC. 2002-12-05 — — US disclosed
EP-1184372-A1 Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) Pfizer Limited (GB) 2002-03-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183303-A1 Phenoxyphenylheterocyclyl derivatives as SSRIs CRHR1, NR3C1, HTR6 KIF11 2354/4885EPHX2 530/4885NR1H4 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback